Boston Scientific’s Revenue Breakdown by Segment (2016-2023)

This statistic highlights Boston Scientific’s Revenue by Segment, split between Cardiovascular, MedSurg, Rhythm & Neuro, and Speciality Pharmaceuticals, reported on a quarterly basis from 2016 onwards.

Boston Scientific’s Revenue by Segment

(All figures in billions, except percentages)

Boston Scientific’s total revenue grew from $2.658 billion earned in Q3 2020 to $2.932 billion earned in Q3 2021, registering a growth of 10% on a year-on-year basis. It fell from $3.077 billion earned in Q2 2021 to $2.932 billion earned in Q3 2021, marking a decrease of 5% on a quarter-on-quarter basis. This decrease is consistent across all its segments.

The cardiovascular segment is the highest contributor of revenue for Boston Scientific, constituing 41% of the total revenue generated by the company and Speciality Pharmaceuticals contributes 0% to the revenue in Q3 2021. The MedSurg segment, and the Rhythm & Neuro segment contributes 31% and 28%, respectively to the total revenue of Boston Scientific in Q3 2021.

Based on segments, Boston Scientific’s Revenue can be bifurcated as follows:

Cardiovascular

This segment includes the Interventional Cardiology and Peripheral intervention business lines of the company.

This segment accounts for the highest share of Boston Scientific’s revenue, with a share of 41% in the revenue generated in Q3 2021, amounting to $1.196 billion. It increased from $1.022 billion earned in Q3 2020 to $1.196 billion earned in Q3 2021, marking a growth of 19% on a year-on-year basis. It decreased from $1.263 billion earned in Q2 2021 to $1.196 billion earned in Q3 2021, marking a fall of 5% on a quarter-on-quarter basis.

MedSurg

This segment includes the Endoscopy, Urology and Pelvic Health business lines of the company.

This segment accounts for 31% of Boston Scientific’s total revenue as per Q3 2021, amounting to $0.917 billion. It increased from $0.825 billion earned in Q3 2020 to $0.917 billion earned in Q3 2021, marking a growth of 11% on a year-on-year basis. It witnessed a decline from $0.948 billion earned in Q2 2021 to $0.917 billion earned in Q3 2021, marking a fall of 3% on a quarter-on-quarter basis.

Rhythm and Neuro

This segment includes the cardiac rhythm management, Electrophysiology and Neuromodulation business lines of the company.

This segment accounts for 28% of the company’s total revenue generated in Q3 2021, amounting to $0.819 billion. It increased from $0.757 billion earned in Q3 2020 to $0.819 billion earned in Q3 2021, marking a growth of 8% on a year-on-year basis. It decreased from $0.866 billion earned in Q2 2021 to $0.819 billion earned in Q3 2021, marking a fall of 5% on a quarter-on-quarter basis. 

Speciality Pharmaceuticals

The contribution of Speciality Pharmaceuticals to the revenue stood at $0.074 billion in Q3 2020. However, on March 1, 2021, the company divested its speciality pharmaceuticals business for $800 million and has since stopped reporting it as a segment. Thus, it has generated no revenue in Q2 2021 and Q3 2021.

About Boston Scientific Corp

Boston Scientific Corporation is a scientific tool producer that focuses on interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. The corporation presently has 36,000 personnel and is established in Marlborough, Massachusetts, United States. It was founded by John Abele and Peter Nicholas. It operates on the medical device industry. Some of its subsidiaries are Preventice, Guidant, Vertiflex, among many others.

Its personnel has a completely advantageous opinion of the corporation. Boston Scientific was ranked forty-third out of one hundred agencies withinside the Glassdoor website’s 2019 Best Places to Work – Employees Choice Survey, with a mean rating of four out of five feasible stars. Current and previous personnel supplied enter for this survey. Women make up 43% of Boston Scientific’s workforce, 38% of control jobs, and 23% of company pinnacle control positions. The corporation closely is based on Acquisitions and has obtained higher than forty agencies since 2004.

The Taxus Stent, a drug-eluting stent meant to unblock clogged arteries, is considered one of Boston Scientific’s most famous products. Cameron Health is regarded for turning in a minimally invasive implantable cardioverter-defibrillator (ICD) known as the EMBLEM subcutaneous implantable defibrillator whilst it changed into absolutely obtained in June 2012. The corporation is presently traded on the New York Stock Exchange with the ticker ‘BSX’ and is a part of the S&P 500 Index.

Did you like Boston Scientific’s Revenue by Segment statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.